Literature DB >> 24249115

Warfarin: not dead yet.

Adam J Rose1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24249115      PMCID： PMC3930771          DOI： 10.1007/s11606-013-2708-6

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  8 in total

1.  Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective.

Authors:  J Hirsh; S M Bates
Journal:  Ann Intern Med       Date:  2001-03-06       Impact factor: 25.391

Review 2.  Measuring quality of oral anticoagulation care: extending quality measurement to a new field.

Authors:  Adam J Rose; Dan R Berlowitz; Susan M Frayne; Elaine M Hylek
Journal:  Jt Comm J Qual Patient Saf       Date:  2009-03

3.  Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Authors:  James V Freeman; Ruo P Zhu; Douglas K Owens; Alan M Garber; David W Hutton; Alan S Go; Paul J Wang; Mintu P Turakhia
Journal:  Ann Intern Med       Date:  2010-11-01       Impact factor: 25.391

4.  Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.

Authors:  Mattias Wieloch; Anders Själander; Viveka Frykman; Mårten Rosenqvist; Niclas Eriksson; Peter J Svensson
Journal:  Eur Heart J       Date:  2011-05-26       Impact factor: 29.983

5.  Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.

Authors:  Shimoli V Shah; Brian F Gage
Journal:  Circulation       Date:  2011-05-23       Impact factor: 29.690

6.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

Authors:  Lars Wallentin; Salim Yusuf; Michael D Ezekowitz; Marco Alings; Marcus Flather; Maria Grazia Franzosi; Prem Pais; Antonio Dans; John Eikelboom; Jonas Oldgren; Janice Pogue; Paul A Reilly; Sean Yang; Stuart J Connolly
Journal:  Lancet       Date:  2010-09-18       Impact factor: 79.321

7.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Ansell; Jack Hirsh; Elaine Hylek; Alan Jacobson; Mark Crowther; Gualtiero Palareti
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.

Authors:  Joyce H S You
Journal:  J Gen Intern Med       Date:  2013-10-17       Impact factor: 5.128
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.